参考文献/References:
[1] Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention[J]. Lancet Neurol, 2016, 15(12): 1257-1272.
[2] Delgado-Alvarado M, Gago B, Navalpotro-Gomez I, et al. Biomarkers for dementia and mild cognitive impairment in Parkinson’s disease[J]. Mov Disord, 2016, 31(6): 861-881.
[3] 常庆庆,李红燕.帕金森病患者血脂、胱抑素C及同型半胱氨酸水平分析[J].中国临床神经科学,2018,26(5):495-501.
[4] Li J, Gu CZ, Zhu M, et al. Correlations between blood lipid, serum cystatin C, and homocysteine levels in patients with Parkinson’s disease[J]. Psychogeriatrics, 2020, 20(2): 180-188.
[5] 中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍学组.中国帕金森病治疗指南(第4版)[J].中华神经科杂志,2020,53(12): 973-986.
[6] Guo X, Song W, Chen K, et al. The serum lipid profile of Parkinson’s disease patients: a study from China[J]. Int J Neurosci, 2015, 125(11): 838-844.
[7] Rozani V, Gurevich T, Giladi N, et al. Higher serum cholesterol and decreased Parkinson’s disease risk: A statin-free cohort study[J]. Mov Disord, 2018, 33(8): 1298-1305.
[8] Fang F, Zhan Y, Hammar N, et al. Lipids, apolipoproteins, and the risk of parkinson disease[J]. Circ Res, 2019, 125(6): 643-652.
[9] Gaig C, Tolosa E. When does Parkinson’s disease begin?[J]. Mov Disord, 2009, 24(Suppl 2): S656-S664.
[10] Berg AL, Rafnsson AT, Johannsson M, et al. The effects of adrenocorticotrophic hormone and an equivalent dose of cortisol on the serum concentrations of lipids, lipoproteins, and apolipoproteins[J]. Metabolism, 2006, 55(8): 1083-1087.
[11] Bahrami A, Barreto G, Lombardi G, et al. Emerging roles for high-density lipoproteins in neurodegenerative disorders[J]. Biofactors, 2019, 45(5): 725-739.
[12] Fu X, Wang Y, He X, et al. A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson’s disease[J]. Lipids Health Dis, 2020, 19(1): 97.
[13] Klemann C, Martens G, Sharma M, et al. Integrated molecular landscape of Parkinson’s disease[J]. NPJ Parkinsons Dis, 2017, 3: 14.
[14] Mauch DH, N?ler K, Schumacher S, et al. CNS synaptogenesis promoted by glia-derived cholesterol[J]. Science, 2001, 294(5545): 1354-1357.
[15] Vitali C, Wellington CL, Calabresi L. HDL and cholesterol handling in the brain[J]. Cardiovasc Res, 2014, 103(3): 405-413.
[16] Anstey KJ, Ashby-Mitchell K, Peters R. Updating the evidence on the association between serum cholesterol and risk of Late-Life dementia: review and Meta-Analysis[J]. J Alzheimers Dis, 2017, 56(1): 215-228.
[17] Huang X, Ng SY, Chia NS, et al. Higher serum triglyceride levels are associated with Parkinson’s disease mild cognitive impairment[J]. Mov Disord, 2018, 33(12): 1970-1971.
[18] N?ga K, Gustavsson AM, Stomrud E, et al. Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later[J]. Neurology, 2018, 90(1): e73-e81.
[19] Banks WA, Farr S, Salameh TS, et al. Triglycerides cross the blood-brain barrier and induce central leptin and insulin receptor resistance[J]. Int J Obes(Lond), 2018, 42(3): 391-397.
[20] Hasnain M, Vieweg W. Possible role of vascular risk factors in alzheimer’s disease and vascular dementia[J]. Curr Pharm Des, 2014, 20(38): 6007-6013.
[21] Freeman LR, Granholm AC. Vascular changes in rat hippocampus following a high saturated fat and cholesterol diet[J]. J Cereb Blood Flow Metab, 2012, 32(4): 643-653.
[22] Trevi? S, Aguilar-Alonso P, Flores HJ, et al. A high calorie diet causes memory loss, metabolic syndrome and oxidative stress into hippocampus and temporal cortex of rats[J]. Synapse, 2015, 69(9): 421-433.
[23] Ahmed RM, Macmillan M, Bartley L, et al. Systemic metabolism in frontotemporal dementia[J]. Neurology, 2014, 83(20): 1812-1818.